ALTHEOS
Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.
ALTHEOS
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2010-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.altheos.net
Total Employee:
11+
Status:
Closed
Contact:
650.989.8570
Email Addresses:
[email protected]
Total Funding:
32.5 M USD
Founder
Investors List
Novo Holdings
Novo Holdings investment in Series A - Altheos
Bay City Capital
Bay City Capital investment in Series A - Altheos
Canaan Partners
Canaan Partners investment in Series A - Altheos
Bay City Capital
Bay City Capital investment in Series A - Altheos
Novo Holdings
Novo Holdings investment in Series A - Altheos
Atheneos Ventures
Atheneos Ventures investment in Series A - Altheos
Canaan Partners
Canaan Partners investment in Series A - Altheos
Life Science Angels
Life Science Angels investment in Series A - Altheos
